Pharmaceutical company Zydus Cadila announced on Saturday that it had received approval from the U.S. health regulator to bring vortioxetine tablets, used to treat depression, to the U.S. market.
The company has received final approval from the United States Food and Drug Administration (USFDA) to market Vortioxetine tablets in strengths of 5 mg, 10 mg, 20 mg, Zydus Cadila said in a statement.
Vortioxetine is used to treat depression. It works by helping to restore the balance of a certain natural substance (serotonin) in the brain.
The drug will be manufactured at the group’s formulation manufacturing plant in the Ahmedabad SEZ, Zydus Cadila noted.
The group now has 322 approvals and has so far filed more than 400 Abbreviated New Drug Applications (ANDAs) since starting the filing process in fiscal year 2003-04, he added. .
(Only the title and image of this report may have been reworked by Business Standard staff; the rest of the content is automatically generated from a syndicated feed.)
Business Standard has always strived to provide up-to-date information and commentary on developments that matter to you and have broader political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these difficult times resulting from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative views and cutting edge commentary on relevant current issues.
However, we have a demand.
As we fight the economic impact of the pandemic, we need your support even more so that we can continue to provide you with more quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscriptions to our online content can only help us achieve the goals of providing you with even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.